These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9605807)

  • 21. Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study.
    Guerrieri-Gonzaga A; Botteri E; Lazzeroni M; Rotmensz N; Goldhirsch A; Varricchio C; Serrano D; Cazzaniga M; Bassi F; Luini A; Bagnardi V; Viale G; Mora S; Bollani G; Albertazzi E; Bonanni B; Decensi A
    Ann Oncol; 2010 May; 21(5):949-54. PubMed ID: 19858087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Long-term results of adjuvant endocrine therapy for hormone receptor-positive breast cancer].
    Semilgazov VF; Manikhas AG; Semiglazov VV; Bozhok AA; Dashian GA; Ivanov VG; Paltuev RM; Vasil'ev AG; Shchedrin DE; Ermachenkova AM; Nikitina IV; Pen'kov KD; Bessonov AA; Tabagua TT; Kolar'kova VV
    Vopr Onkol; 2011; 57(5):567-77. PubMed ID: 22238925
    [No Abstract]   [Full Text] [Related]  

  • 23. [Progesterone receptor in breast cancer: fundamental data and clinical applications].
    Ojasoo T
    Bull Cancer; 1996; 83 Suppl 1():1-5. PubMed ID: 8777338
    [No Abstract]   [Full Text] [Related]  

  • 24. Chemoprevention of breast cancer.
    O'Shaughnessy JA
    JAMA; 1996 May; 275(17):1349-53. PubMed ID: 8614122
    [No Abstract]   [Full Text] [Related]  

  • 25. [Basic Consensus on endocrinotherapy for breast cancer].
    Jiang ZF; Xu BH; Song ST
    Zhonghua Zhong Liu Za Zhi; 2006 Mar; 28(3):238-9. PubMed ID: 16875616
    [No Abstract]   [Full Text] [Related]  

  • 26. [Estrogen and progesterone receptors in breast cancer].
    Sonoo H
    Nihon Rinsho; 2000 Apr; 58 Suppl():146-53. PubMed ID: 11025988
    [No Abstract]   [Full Text] [Related]  

  • 27. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer.
    Steinmann D; Bremer M; Rades D; Skawran B; Siebrands C; Karstens JH; Dörk T
    Br J Cancer; 2001 Sep; 85(6):850-8. PubMed ID: 11556836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing.
    de la Cruz J; Andre F; Harrell RK; Bassett RL; Arun B; Mathieu MC; Delaloge S; Gilcrease MZ
    Hum Pathol; 2012 Nov; 43(11):1932-9. PubMed ID: 22591913
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Are the hereditary forms of BRCA1 and BRCA2 breast cancer sensitive to estrogens?].
    Pujol P; This P; Noruzinia M; Stoppa-Lyonnet D; Maudelonde T
    Bull Cancer; 2004; 91(7-8):583-91. PubMed ID: 15381448
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Breast cancer outcomes by steroid hormone receptor status assessed visually and by computer image analysis.
    Mohammed ZM; Edwards J; Orange C; Mallon E; Doughty JC; McMillan DC; Going JJ
    Histopathology; 2012 Aug; 61(2):283-92. PubMed ID: 22571413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations.
    Duffy SW; Nixon RM
    Br J Cancer; 2002 Jan; 86(2):218-21. PubMed ID: 11870509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predicted anti-oestrogen resistance in BRCA-associated familial breast cancers.
    Osin P; Gusterson BA; Philp E; Waller J; Bartek J; Peto J; Crook T
    Eur J Cancer; 1998 Oct; 34(11):1683-6. PubMed ID: 9893652
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progesterone receptor testing: not the right time to be buried.
    Colozza M; Larsimont D; Piccart MJ
    J Clin Oncol; 2005 Jun; 23(16):3867-8; author reply 3869-70. PubMed ID: 15923594
    [No Abstract]   [Full Text] [Related]  

  • 34. The estrogen receptors alpha, beta, and beta cx.
    Shaaban AM; Speirs V
    Clin Cancer Res; 2005 Nov; 11(22):8222; author reply 8222-3. PubMed ID: 16299256
    [No Abstract]   [Full Text] [Related]  

  • 35. Correlation of hormone receptors with Her-2 Neu protein expression and the histological grade in invasive breast cancers in a cohort of Saudi Arabia.
    Arafah M
    Turk Patoloji Derg; 2012; 28(1):38-43. PubMed ID: 22207430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.
    Goldhirsch A; Glick JH; Gelber RD; Coates AS; Senn HJ
    J Clin Oncol; 2001 Sep; 19(18):3817-27. PubMed ID: 11559719
    [No Abstract]   [Full Text] [Related]  

  • 37. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation.
    Richardson J; Shaaban AM; Kamal M; Alisary R; Walker C; Ellis IO; Speirs V; Green AR; Bell SM
    Breast Cancer Res Treat; 2011 Jun; 127(3):639-48. PubMed ID: 20632086
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is axillary lymph node dissection necessary in elderly patients with breast carcinoma who have a clinically uninvolved axilla?
    Martelli G; Miceli R; De Palo G; Coradini D; Salvadori B; Zucali R; Galante E; Marubini E
    Cancer; 2003 Mar; 97(5):1156-63. PubMed ID: 12599220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen and progesterone receptors in the endometrium of postmenopausal breast cancer patients treated with tamoxifen and progestogens.
    Cohen I; Altaras MM; Beyth Y; Shapira J; Figer A; Tepper R; Cordoba M; Yigal D; Bernheim J
    Gynecol Oncol; 1997 Apr; 65(1):83-8. PubMed ID: 9103396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tamoxifen may be an effective adjuvant treatment for BRCA1-related breast cancer irrespective of estrogen receptor status.
    Foulkes WD; Goffin J; Brunet JS; Bégin LR; Wong N; Chappuis PO
    J Natl Cancer Inst; 2002 Oct; 94(19):1504-6. PubMed ID: 12359859
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.